Coronavirus rna vaccines
AssigneeModernaTX, Inc.
InventorsMihir Metkar, Vladimir Presnyak, Guillaume Stewart-Jones
Life of this patent
Estimating the term…
Abstract
The disclosure relates to coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
Claims32
A messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) that comprises a nucleotide sequence having at least 80% identity to the nucleotide sequence of SEQ ID NO:
- 28 and encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 29.
(canceled)
(canceled)
A composition comprising a lipid nanoparticle and a chemically-modified messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) that comprises a nucleotide sequence having at least 80% identity to the nucleotide sequence of SEQ ID NO:
- 28 and encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 29, wherein the lipid nanoparticle comprises a PEG-modified lipid, a non-cationic lipid, a sterol, an ionizable cationic lipid, or any combination thereof.
-26. (canceled)
A composition comprising:
- (a) a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) that comprises the nucleotide sequence of SEQ ID NO:
- 28;
- and
- (b) a lipid nanoparticle comprising 0.5-15 mol % PEG-modified lipid;
- 5-25 mol % non-cationic lipid;
- 25-55 mol % sterol;
- and 20-60 mol % ionizable cationic lipid, and wherein the ionizable cationic lipid has the structure of Compound 1:
Dependencies are inferred from the claim text.